

[Docetaxel](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CD02](#)

Indication

Unspecified malignant neoplasms of ill-defined or unspecified sites ICD11 code: [2D9Z](#)

INN

Docetaxel

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 20 mg per mL ; 40 mg per mL

EML status history

First added in 2011 ([TRS 965](#))

Removed in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Docetaxel](#)

DrugBank

[Docetaxel](#)

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of docetaxel was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for docetaxel for more information.